Intellia reports patient death in nex-z trial; awaits FDA clinical hold; lonvo-z on track

Intellia Therapeutics, Inc.

Patient who had Grade 4 liver transaminase elevations after nex-z dose in MAGNITUDE Phase 3 trial died; FDA clinical hold letter pending.
Phase 3 HAELO trial of lonvo-z for hereditary angioedema completed enrollment; topline data expected mid-2026.
Cash, equivalents and marketable securities ~$670M as of Sept 30, 2025; company expects to fund ops into mid-2027.
Longer-term Phase 1 clinical data for nex-z in ATTR-CM to be presented Nov 10 at AHA 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.